T2 Biosystems, Inc. TTOO
0.00 USD -0.01 (-96.00%)
Regular-session close
0.11 +0.11 +27,925.00%
After hours · Nov 16, 4:00 PM ET
0.0115 Day range 0.0115
0.0001 52-week range 0.05
- YTD
- -92.00%
- 1 year
- -96.69%
News
defenseworld.net Financial Analysis: Biostage (OTCMKTS:BSTG) and T2 Biosystems (NASDAQ:TTOO) T2 Biosystems (NASDAQ: TTOO - Get Free Report) and Biostage (OTCMKTS:BSTG - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two…
defenseworld.net Reviewing T2 Biosystems (NASDAQ:TTOO) & Acutus Medical (NASDAQ:AFIB) Risk and Volatility Acutus Medical has a beta of -1.28, meaning that its stock price is 228% less volatile than the S&P 500. Comparatively, T2 Biosystems has a beta of 0.88, meaning that its stock…
defenseworld.net T2 Biosystems (NASDAQ:TTOO) Shares Cross Below Two Hundred Day Moving Average – Should You Sell? T2 Biosystems, Inc. (NASDAQ: TTOO - Get Free Report) passed below its two hundred day moving average during trading on Friday. The stock has a two hundred day moving average of $0.02 and traded as…
defenseworld.net T2 Biosystems (NASDAQ:TTOO) versus Minerva Surgical (NASDAQ:UTRS) Head-To-Head Review Valuation and Earnings This table compares Minerva Surgical and T2 Biosystems"s revenue, earnings per share (EPS) and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share…
defenseworld.net T2 Biosystems (NASDAQ:TTOO) Stock Price Passes Above 50 Day Moving Average – Here’s What Happened Shares of T2 Biosystems, Inc. (NASDAQ: TTOO - Get Free Report) passed above its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $0.01 and traded as high…
defenseworld.net T2 Biosystems (NASDAQ:TTOO) Shares Cross Above 50 Day Moving Average – What’s Next? T2 Biosystems, Inc. (NASDAQ: TTOO - Get Free Report)'s share price crossed above its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $0.01 and traded as high…
globenewswire.com T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc. LEXINGTON, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced…
globenewswire.com T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens Intends to accelerate broad adoption of direct-from-whole-blood diagnostics, generate non-dilutive capital, and create a new royalty revenue stream Intends to accelerate broad adoption of…
seekingalpha.com T2 Biosystems, Inc. (TTOO) Q3 2024 Earnings Call Transcript T2 Biosystems, Inc. (NASDAQ:TTOO ) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants Trip Taylor - Investor Relations John Sperzel - Chairman & Chief Executive…
globenewswire.com T2 Biosystems to Report Third Quarter 2024 Financial Results and Business Updates on November 14, 2024 LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today…
seekingalpha.com T2 Biosystems, Inc. (TTOO) Business Update Conference Call Transcript T2 Biosystems, Inc. (NASDAQ:TTOO ) Business Update Conference Call October 10, 2024 4:30 PM ET Company Participants Trip Taylor - IR John Sperzel - Chairman and CEO Conference Call Participants…
globenewswire.com T2 Biosystems to Host Business Update Call on October 10, 2024 LEXINGTON, Mass., Oct. 08, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today…
globenewswire.com T2 Biosystems Announces Exclusive U.S. Agreement with Cardinal Health to Sell its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens LEXINGTON, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes,…
globenewswire.com T2 Biosystems Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the European Union LEXINGTON, Mass., Sept. 20, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes,…
globenewswire.com T2 Biosystems to Participate in the H.C. Wainwright 26th Annual Global Investment Conference LEXINGTON, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced…
globenewswire.com T2 Biosystems to Attend Upcoming Investor Conferences LEXINGTON, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced…
seekingalpha.com T2 Biosystems, Inc. (TTOO) Q2 2024 Earnings Call Transcript T2 Biosystems, Inc. (NASDAQ:TTOO ) Q2 2024 Earnings Conference Call July 29, 2024 4:30 PM ET Company Participants Trip Taylor - Investor Relations John Sperzel - Chairman & Chief Executive Officer…
globenewswire.com T2 Biosystems Announces Commercial Expansion Through Malaysia and Indonesia Distributor LEXINGTON, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the…
globenewswire.com T2 Biosystems to Report Second Quarter 2024 Financial Results and Business Updates on July 29, 2024 LEXINGTON, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today…
globenewswire.com T2 Biosystems Regains Compliance with Nasdaq Continued Listing Requirements LEXINGTON, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes,…
